GlobalData Healthcare

Are you attending #ADPD2025? Erela Dana and Philippa Salter will be there and would love to meet with you! Reach out to them today to arrange a time to chat. #Alzheimers #Parkinsons #Neuroscience #DrugDevelopment

Is smaller pharma becoming the new face of innovation in #drugdevelopment? FDA #drugapprovals may have dropped 15.44% in 2024 — but innovation has not slowed down. Smaller biopharma companies are stepping up, addressing unmet medical needs and leveraging contract development and manufacturing organizations (#CDMOs) to bring breakthrough #therapies to market, reveals GlobalData Plc. #GlobalData’s Bio/Pharmaceutical #Outsourcing #Report explores how these nimble players are overcoming complex manufacturing challenges and driving the next wave of #pharmaceutical growth. Adam Bradbury, #Pharma Analyst at GlobalData, notes: “These companies are not only addressing critical gaps in #patientcare but are also leveraging the expertise of CDMOs to overcome #manufacturing complexities, ensuring they can scale innovative therapies in an increasingly competitive market.” Inside the February 2025 report: • #FDA approval trends & CDMO strategies • Latest #contractmanufacturing deals • Key #MandA, #financing, and #regulatory developments • Facility-level insights and #GMP updates Whether you are a CMO leader, sourcing executive, or investor—this report is your strategic compass. Get ahead. Stay informed. Buy now👉 https://lnkd.in/gQUSumyf #DecodetheFuture with GlobalData Plc GlobalData Healthcare Fiona Barry Katarina Zahedi Kathryn Kinch Amanda Murphy Revati Tatake #PharmaIndustry #Biopharma #PharmaInnovation #ContractManufacturing #Pharmaceuticals #LifeSciences #HealthcareStrategy

Big smiles all round at #BioEuropeSpring in Milan! Our team are on the ground, discussing in-licensing opportunities in academia and supporting out-licensing discussions between our biotech and pharma clients. If you see them around, don't hesitate to say hello or reach out to Barzani, Shakib, Deepen, Teo, Sara, or Jack to arrange a time to chat! 🖐️ #BioEurope2025 #Licensing #BioTech #Innovation

🚀 Our very own Stanley Willis is off to LogiPharma 2025 in Lyon! From April 8-10, Stanley will be joining supply chain leaders to discuss AI, sustainability goals, heightened geopolitical risks, and increasingly complex products. Don't forget to say hi if you see him around, and reach out on LinkedIn if you'd like to arrange a time to chat! #LogiPharma #LogiPharma2025 #MedTech #SupplyChain

Hot off the press, our team on the ground at #AAD2025 have some exciting updates to report! 🔥 Johnson & Johnson revealed highly anticipated late-breaking Phase III ICONIC-LEAD results in #psoriasis for their novel IL-23 receptor antagonist, icotrokinra, showing outstanding, robust efficacy and a favorable safety profile as a first-of-its kind oral therapy!  J&J also unveiled supportive pediatric data for Tremfya (guselkumab), the potential first-in-class anti-IL-23p19 for these patients, from the Phase III PROTOSTAR trial.  In other news, Galderma debuted their eagerly awaited commercial booth for Nemluvio, the first-in-class anti-IL-31 biologic, aiming to disrupt the fiercely competitive #atopicdermatitis space, placing rapid itch relief at the forefront with “𝘐𝘵𝘤𝘩 𝘙𝘦𝘭𝘪𝘦𝘧 *𝘤𝘭𝘪𝘤𝘬𝘴 𝘧𝘪𝘯𝘨𝘦𝘳𝘴* 𝘭𝘪𝘬𝘦 𝘵𝘩𝘢𝘵."

Are you attending #AAD2025? We'll be there, and we'd love to meet with you! Reach out to one of our analysts to arrange a time to chat. Tanuj Sircar, Managing Analyst Ash Chinyanganya, Senior Analyst Stephanie Ngan, CI Analyst Kieran Walker, CI Analyst #AtopicDermatitis #Psoriasis #AlopeciaAreata #PsoriaticArthritis

Clinical trials are becoming more expensive due to complex designs and sites in multiple countries, says GlobalData Healthcare Business Fundamentals analyst Alison Labya at Clinical Trial Supply Europe in Barcelona today. #clinicaltrials #clinicaltrialsupply #CTSEurope

Live from ECCO 2025 in Berlin! The energy is high as pharma leaders showcase groundbreaking IBD innovations.   Eli Lilly and Company’s Omvoh (mirikizumab) dominates headlines with its "NOW APPROVED FOR CD" branding, following its recent EU approval, while Pfizer spotlights Velsipity (etrasimod) as the only oral, first-line advanced therapy for UC indicated for patients 16 years of age and older.  Meanwhile, MSD’s anti-TL1A, tulisokibart, and Abivax’s RNA-based obefazimod are generating buzz in the pipeline space.  With new approvals, patient-centric solutions, and cutting-edge mechanisms of action, ECCO 2025 is shaping the future of IBD treatment.  #IBD #ECCO2025 #Innovation #Omvoh #Velsipity #Skyrizi #Tulisokibart #Obefazimod 

Exciting news from Deallus, Jack Florio will be speaking at the prestigious Drug Discovery Innovation Programme in San Diego. Bringing together top minds in drug discovery to explore the future of pharmaceutical science, #DDIP2025 offers a unique opportunity to exchange insights with key industry leaders and accelerate the pace of drug discovery. Attending DDIP? Jack would love to connect! Reach out to schedule a chat during the conference.  #DDIP #DrugDiscovery #Innovation #Biotech

Stanley Willis and Owen Jenkins-Garcia will soon be heading to Barcelona for the 26th Annual Clinical Trial Supply Europe 2025! 🚀 Drop them a message today to arrange a time to chat, or find them on the ground at Booth 52! #ClinicalTrialSupplyEurope #ClinicalTrial #SupplyChain